SeekingAlpha · Oct 31, 2026
AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript
AstraZeneca PLC (AZN) Q3 2026 Earnings Call October 30, 2026 10:30 AM EDTCompany ParticipantsJoris Silon - Head of Investor RelationsPascal Soriot - CEO...
NYSE · AZN
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
$186.65
Up+$12.25 (+7.02%)
Updated Oct 31, 2026, 4:28 PM
SID Score
7.9/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 279.95B
- P/E ratio
- 33.06
- Dividend yield
- 0.82%
- 52-week range
- $80.48 – $212.71
- Volume
- 5.47M
- Avg. volume
- 5.47M
Price performance · AZN
AZN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
AZN closed at $186.65 after 21 trading sessions, up 18.96% for the selected period.
- Last close
- $186.65
- Period change
- +18.96%
- Period low
- $155.82
- Period high
- $186.65
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $183.59 | $188.39 | $183.10 | $186.65 | 5.47M |
| Oct 29, 2026 | $173.26 | $175.35 | $172.87 | $174.40 | 3.72M |
| Oct 28, 2026 | $168.645 | $171.94 | $167.96 | $169.51 | 1.7M |
| Oct 27, 2026 | $169.68 | $171.72 | $169.4501 | $170.08 | 2.91M |
| Oct 26, 2026 | $171.54 | $172.37 | $170.675 | $172.06 | 3.31M |
| Oct 23, 2026 | $171.28 | $171.75 | $169.51 | $171.49 | 3.69M |
| Oct 22, 2026 | $169.86 | $173.91 | $169.32 | $172.57 | 2.77M |
| Oct 21, 2026 | $168.91 | $169.84 | $168.09 | $168.45 | 1.9M |
| Oct 20, 2026 | $166.77 | $169.235 | $166.66 | $168.82 | 4.59M |
| Oct 19, 2026 | $164.51 | $166.10 | $163.91 | $163.95 | 2.32M |
| Oct 16, 2026 | $166.97 | $167.18 | $164.365 | $165.41 | 3.46M |
| Oct 15, 2026 | $167.69 | $169.81 | $166.49 | $166.68 | 4.4M |
| Oct 14, 2026 | $158.71 | $162.71 | $158.31 | $162.03 | 3.33M |
| Oct 13, 2026 | $160.76 | $160.83 | $154.00 | $155.82 | 3.11M |
| Oct 12, 2026 | $159.44 | $159.44 | $157.60 | $158.33 | 2.86M |
| Oct 9, 2026 | $159.45 | $160.065 | $158.53 | $159.20 | 2.12M |
| Oct 8, 2026 | $159.80 | $160.05 | $156.72 | $158.78 | 3.49M |
| Oct 7, 2026 | $159.12 | $161.29 | $158.53 | $160.12 | 2.46M |
| Oct 6, 2026 | $159.795 | $159.96 | $156.26 | $158.61 | 2.05M |
| Oct 5, 2026 | $156.76 | $157.20 | $154.81 | $156.53 | 2.26M |
| Oct 2, 2026 | $158.46 | $158.795 | $156.41 | $156.90 | 3.04M |
Latest AZN news
The latest Smart Investors Daily articles mentioning AZN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AZN research
Overview
Company profile and research snapshot.
Company profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $102.67
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Berenberg Bank | Buy | — |
| Jun 26, 2026 | Deutsche | Sell | — |
| Jun 26, 2026 | Jefferies | Buy | — |
| Jun 11, 2026 | Deutsche | Sell | — |
| Jun 9, 2026 | Jefferies | Buy | — |
News briefing
Generated Oct 31, 2026, 3:05 PM
Why Is AZN Up 7% Today?
AstraZeneca delivered a Q3 earnings beat that exceeded Wall Street expectations, with oncology drugs driving robust sales growth and CEO outlining a compelling $20 billion revenue opportunity. The strong results and forward guidance have investors optimistic about the company's turnaround narrative, sending shares to three-month highs.
Bottom line: Today's 7% rally reflects genuine operational progress—a clean earnings beat, oncology momentum, and credible management guidance on a $20 billion growth opportunity—though investors should monitor execution risk and pipeline setbacks like Ultomiris. The bull case hinges on AstraZeneca delivering on its ambitious revenue targets and maintaining oncology momentum, while the company must prove it can navigate development failures without derailing shareholder returns.
Yahoo · Oct 30, 2026
AstraZeneca Gaps Up To Three-Month High As CEO Calls Out $20 Billion Potential
AstraZeneca stock gapped higher Friday as cancer drugs Enhertu and Tagrisso lent themselves to a solid third-quarter report.
Yahoo · Oct 30, 2026
COVID Vaccine Giant AstraZeneca Stock Jumps 7%. What's Behind It?
AstraZeneca Q3 earnings beat forecasts as the drugmaker launches a $1.5 billion savings plan to fund its AI-backed pipeline.
Yahoo · Oct 30, 2026
AstraZeneca Q3 Earnings Call Highlights
AstraZeneca (NYSE:AZN) reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology, while loss-of-exclusivity pressures weighed on parts of its cardiovascular, renal and metabolism port
AI research layers
Interpretive context generated from the platform’s current data sources.
AstraZeneca PLC Stock Performance
AstraZeneca PLC shares have demonstrated strong momentum across multiple timeframes, trading at $186.65 per SID market data. The stock has gained 8.01% over the past month and 2.81% over the trailing three months, while the one-year return stands at an impressive 107.47%. AZN currently trades well above both its 50-day moving average of $164.04 and its 200-day moving average of $174.10, indicating sustained bullish technical positioning. The 14-day RSI reads 71.5, placing the stock at the threshold of overbought territory, which may signal potential near-term consolidation. Notably, AstraZeneca carries a beta of just 0.168, per Massive/Polygon data, reflecting significantly lower volatility than the broader market. Average daily trading volume stands at approximately 5.47 million shares. The company commands a market capitalization of roughly $279.9 billion, positioning it among the largest global pharmaceutical firms by market value.
AstraZeneca PLC Valuation Analysis
AstraZeneca currently trades at a price-to-earnings ratio of 33.06, reflecting a premium valuation relative to many healthcare sector peers, per SID market data. The PEG ratio stands at 4.53, suggesting that the stock's earnings growth rate does not fully justify its elevated P/E multiple at current levels. The price-to-book ratio registers at 6.24, indicating that investors are paying more than six times the company's book value per share, according to SEC filings. AstraZeneca offers a dividend yield of approximately 1.56%, providing a modest income component for shareholders. Within the broader healthcare sector, the company's valuation metrics reflect market confidence in its pipeline and revenue trajectory, though the premium pricing leaves limited margin for execution missteps. The $279.9 billion market capitalization underscores AstraZeneca's standing as a mega-cap pharmaceutical entity with significant global operational scale across oncology, cardiovascular, and respiratory therapeutic areas.
Smart Money Activity for AZN
AstraZeneca's composite smart money score stands at 59 out of 100 with a neutral signal, per SID market data. Institutional positioning is notably strong, scoring a perfect 25 out of 25, indicating robust accumulation by major fund managers according to 13F institutional filings. Insider activity scores 12.5 out of 25, with three insider transactions recorded over the past 90 days — all three classified as purchases and zero sells — per SEC Form 4 filings. This unanimous insider buying pattern suggests internal confidence in the company's forward trajectory. Congressional trading activity scores 12 out of 25, reflecting moderate engagement by lawmakers. Dark pool activity registers at 9.4 out of 25, suggesting relatively limited off-exchange institutional block trading in recent periods. The divergence between the maximum institutional score and the below-average dark pool score creates a mixed composite reading. Taken together, the strongest signal emerges from institutional holders maintaining full conviction alongside consistent insider purchasing behavior in the most recent quarter.
AstraZeneca PLC Earnings Outlook
AstraZeneca has delivered substantial earnings surprises in its most recently reported quarters, per company earnings reports. The company posted actual earnings of $2.63 per share against a consensus estimate of $1.52, representing a positive surprise of $1.11 for the period ending July 2026. In the subsequent reporting period, AstraZeneca reported $2.79 per share versus an estimate of $1.44, delivering an even larger $1.35 beat. These consecutive outsized surprises indicate the company has consistently outperformed analyst expectations by significant margins. Looking ahead, analyst estimates project earnings of $1.44 per share for the quarter expected to be reported on July 28, 2026, and $1.35 per share for the November 5, 2026 period. The pattern of actual results substantially exceeding forecasts suggests analysts may still be underestimating AstraZeneca's earnings power, though future estimates have yet to be fully revised upward to reflect recent outperformance trends.
Wall Street Analyst Ratings for AZN
Wall Street coverage of AstraZeneca reflects a divided outlook among major research firms, per SID consensus data. Berenberg Bank issued its most recent rating on July 13, 2026, reiterating a Buy recommendation on AZN shares. Jefferies has also maintained a Buy rating, reiterating on both June 9 and June 26, 2026, signaling consistent bullish conviction from the firm. In contrast, Deutsche Bank stands as a notable bear, reiterating a Sell rating on June 11 and again on June 26, 2026, per Wall Street analyst reports. This creates a clear split among the three most recently active coverage firms, with two maintaining Buy ratings and one holding a Sell. The divergence underscores differing views on AstraZeneca's valuation sustainability at a 33.06 P/E ratio and 4.53 PEG ratio. The absence of Hold ratings among recent coverage actions suggests analysts hold strong directional convictions rather than neutral stances on AZN's risk-reward profile at current trading levels.
